+91 80 2808 2808

Update on U.S. FDA Inspection at Biocon Biologics’ Manufacturing Facility in Johor, Malaysia

  • Posted by: BIOCON



Bengaluru, Karnataka, India, October 18, 2023

“Biocon Sdn Bhd., a step-down subsidiary of Biocon Biologics Limited has received a communication from the U.S. Food and Drug Administration (FDA) pursuant to its July 2023 cGMP inspection at its insulins manufacturing facility at Johor, Malaysia. The FDA has determined the inspection classification as “OAI” (Official Action Indicated). The OAI status may cause delay and/or withholding of pending product approvals or supplements from the facility.

We submitted a comprehensive Corrective and Preventive Action (CAPA) plan to the FDA in response to observations from the July inspection and believe we are on track to complete all actions as committed. The Company will continue to engage with the Agency to understand any outstanding concerns and work closely to address them expeditiously.

We do not believe that this will have a material impact on the manufacturing and distribution of the Company’s commercial products for the US market. Biocon Biologics remains committed to bringing high-quality and affordable medicines to patients in the United States.”

For more information email to

Author: BIOCON
Leaving the Biocon site!

You are now leaving the Biocon website for a Biocon affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree >>